Psilocybin Mushrooms (Psilocybe spp.) — Clinical Therapeutic Context

Psilocybin mushrooms (primarily Psilocybe cubensis and related species) are included on this list in one strictly defined context: as a subject of the most actively advancing clinical neuroscience research of the 2020s, with implications for brain health that dwarf any other entry on this list — but exclusively within regulated clinical and therapeutic settings. Psilocybin is a Schedule I controlled substance in most jurisdictions worldwide. It is not available as a supplement, is not recommended for unsupervised use, and will not be found at a health food retailer. Its placement here is a factual accounting of the science, not a recommendation for consumer use. The clinical evidence base in 2025–2026 is extraordinary by any standard. COMPASS Pathways' COMP360 (pharmaceutical-grade synthetic psilocybin) has produced two positive Phase 3 randomized controlled trials for treatment-resistant depression — the strongest clinical dataset any classic psychedelic compound has ever generated. An NDA submission is targeted for Q4 2026, with a potential FDA approval decision by early 2027. COMP360 retains its FDA Breakthrough Therapy Designation. CYB003, a deuterated psilocybin analog from Cybin Inc., has received FDA Breakthrough Therapy Designation for major depressive disorder, with Phase 2 data showing 75% of participants who received two doses at 16 mg achieving remission — an outcome that vastly exceeds the 20–30% remission rates typical of SSRIs. AbbVie acquired Gilgamesh Pharmaceuticals for $1.2 billion in August 2025 to gain access to bretisilocin (GM-2505), a psilocybin analog in Phase 2 for MDD. Psilocybin acts primarily on serotonin 5-HT2A receptors in the prefrontal cortex, producing rapid and sustained increases in neuroplasticity, synaptic connectivity, and BDNF expression — effects that persist far beyond the acute experience through mechanisms that are now the subject of intense academic investigation. These neuroplasticity effects are mechanistically distinct from and pharmacologically unrelated to any compound in functional mushrooms. The two categories do not overlap.